Nov. 26 at 1:05 AM
$DRTS How would y’all feel about a buyout at some point in the future? Itwould likely happen in late 26’ - early 27’, after critical data report-out and approval thresholds are met but before infrastructure scaling, logistics complexity, and supply chain development.
We know the M&A space is hot now, with large bio and pharma companies scooping up promising startups. Similar (but inferior) programs have been bought between 2-3B. I’d be open to it at a 3-5B market cap (30-50 / share) but would prefer if we went our own way. If we’re looking at
$100B in TAM across the currently targeted diseases, a 10% capture of that market would easily put us in the 5-10B valuation at .5-1x sales or 3-5x earnings.
Strategic partnerships seem much better overall, and if things work out well, I think
$50+ share is within scope by 2030
